Maintenance of long-term remission using oral administration of low-dose etoposide in a patient demonstrating a relapse of blastic natural killer-cell lymphoma.
Hatano
Y
Y
Ogata
M
M
Ohishi
M
M
Anan
T
T
Senba
K
K
Yasumatsu
T
T
Katagiri
K
K
Kashima
K
K
Yokoyama
S
S
Kadota
J-I
JI
Takayasu
S
S
Fujiwara
S
S
D000284:Administration, Oral; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007694:Killer Cells, Natural; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D008297:Male; D012074:Remission Induction / Q000379:methods; D055502:Secondary Prevention; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide